A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
/in Checkpoint-Inhibitors, Colorectal Cancer, Dendritic Cells, International Publications /von 2022-09-09 / Cancer Immunol Immunother 2023 Apr;72(4):827-840Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2022-06-17 / Pharm Res 2022 Aug;39(8):1851-1866Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2021-07-19 / Sci Rep 2021 Jul;11(1):14661Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-11-16 / Int J Mol Sci 2020 Nov;21(22)Emerging Immunotherapies in the Treatment of Brain Metastases
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-10-26 / Oncologist 2020 Oct;Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-08-07 / Cancer Cell Int. 2020;20:380Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2020-06-21 / J Control Release 2020 Jun;326:63-74Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-12 / Front Oncol 2020;10:343TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2020-02-01 / J Immunother Cancer 2020 02;8(1)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de